OriCiro: replacing conventional bacterial cloning

OriCiro aims to provide plasmid DNA manufacturing to pharmas using a cell-free method of in vitro genome propagation that could be safer and faster than conventional Escherichia coli cloning.

OriCiro Genomics Inc. launched in April 2019 with $3.6 million in series A funding from University of Tokyo Edge Capital to manufacture its first product  — a reagent kit for assembly and amplification of large DNA marketed to academic and nonprofit researchers. The company launched the kit in Japan in June and anticipates a global launch by year-end. ...